Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboxymethylcellulose + glycerin
- Development stage
- Phase 3
- Lead developer
- Allergan
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Small Molecules, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
Refresh Optive is a topical ophthalmic lubricant formulation developed by Allergan for the symptomatic relief of dry eye disease. It is a combination product containing carboxymethylcellulose sodium (CMC) and glycerin. CMC is a high-molecular-weight polymer that acts as a mucoadhesive lubricant, increasing tear viscosity and prolonging retention time on the ocular surface by binding to corneal epithelial cells. Glycerin serves as a demulcent and osmoprotectant, helping to shield the ocular surface from the damaging effects of hyperosmolarity, which is a primary driver of inflammation and cell damage in dry eye syndrome. The product line includes various formulations, such as preservative-free single-use vials and multi-dose bottles, as well as specialized versions like Refresh Optive Mega-3, which incorporates flaxseed and omega-3 oils to support the lipid layer of the tear film.
- Brand names
- Refresh OptiveOptiveRefresh Optive Mega-3Refresh Optive Gel DropsRefresh Optive AdvancedRefresh Optive SensitiveRefresh Optive FusionOptive UD
- Other names
- CMC-glycerin ophthalmic solutioncarboxymethylcellulose sodium and glycerin ophthalmic solution
Beyond the preview
Go deeper on carboxymethylcellulose + glycerin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboxymethylcellulose + glycerin.